Abstract:BACKGROUND The expression of the membrane receptor protein GFRA1 is frequently upregulated in many cancers, which can promote cancer development by activating the classic RET-RAS-ERK and RET-RAS-PI3K-AKT pathways. Several therapeutic anti-GFRA1 antibody-drug conjugates are under development. Demethylation (or hypomethylation) of GFRA1 CpG islands (dmGFRA1) is associated with increased gene expression and metastasis risk of gastric cancer. However, it is unknown whether dmGFRA1 affects the metastasis of other cancers, including colon cancer (CC). AIM To study whether dmGFRA1 is a driver for CC metastasis and GFRA1 is a potential therapeutic target. METHODS CC and paired surgical margin tissue samples from 144 inpatients and normal colon mucosal biopsies from 21 noncancer patients were included in this study. The methylation status of GFRA1 islands was determined by MethyLight and denaturing high-performance liquid chromatography and bisulfite-sequencing. Kaplan-Meier analysis was used to explore the effect of dmGFRA1 on the survival of CC patients. Impacts of GFRA1 on CC cell proliferation and migration were evaluated by a battery of biological assays in vitro and in vivo. The phosphorylation of AKT and ERK proteins was examined by Western blot analysis. RESULTS The proportion of dmGFRA1 in CC, surgical margin, and normal colon tissues by MethyLight was 68.4%, 73.4%, and 35.9% (median; nonparametric test, P = 0.001 and < 0.001), respectively. Using the median value of dmGFRA1 peak area proportion as the cutoff, the proportion of dmGFRA1-high samples was much higher in poorly differentiated CC samples than in moderately or well-differentiated samples (92.3%% vs 55.8%, Chi-square test, P = 0.002) and significantly higher in CC samples with distant metastasis than in samples without (77.8% vs 46.0%, P = 0.021). The overall survival of patients with dmGFRA1-low CC was significantly longer than that of patients with dmGFRA1-high CC (adjusted hazard ratio = 0.49, 95% confidence interval: 0.24-0.98), especially for 89 CC patients with metastatic CC (adjusted hazard ratio = 0.41, 95% confidence interval: 0.18-0.91). These data were confirmed by the mining results from TCGA datasets. Furthermore, GFRA1 overexpression significantly promoted the proliferation/invasion of RKO and HCT116 cells and the growth of RKO cells in nude mice but did not affect their migration. GFRA1 overexpression markedly increased the phosphorylation levels of AKT and ERK proteins, two key molecules in two classic GFRA1 downstream pathways. CONCLUSION GFRA1 expression is frequently reactivated by DNA demethylation in CC tissues and is significantly associated with a poor prognosis in patients with CC, especially those with metastatic CC. GFRA1 can promote the proliferation/growth of CC cells, probably by the activation of AKT and ERK pathways. GFRA1 might be a therapeutic target for CC patients, especially those with metastatic potential.

Tumor-associated Macrophage-Derived GDNF Promotes Gastric Cancer Liver Metastasis Via a GFRA1-modulated Autophagy Flux

Emerging Molecular Basis of Hematogenous Metastasis in Gastric Cancer

MAPK4 Silencing in Gastric Cancer Drives Liver Metastasis by Positive Feedback Between Cancer Cells and Macrophages.

Data from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Prognostic Role of Myeloid-Derived Tumor-Associated Macrophages at the Tumor Invasive Margin in Gastric Cancer with Liver Metastasis (GCLM): a Single-Center Retrospective Study.

Rage Expression In Tumor-Associated Macrophages Promotes Angiogenesis In Glioma

Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis

Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer

GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy

Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer.

Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer

Tumour-associated macrophages in gastric cancer: From function and mechanism to application

SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies

Activated HIF1α of Tumor Cells Promotes Chemoresistance Development Via Recruiting GDF15-producing Tumor-Associated Macrophages in Gastric Cancer.

Tumor-derived LIF Promotes Chemoresistance Via Activating Tumor-Associated Macrophages in Gastric Cancers

A novel TGFbeta/TGILR axis mediates crosstalk between cancer-associated fibroblasts and tumor cells to drive gastric cancer progression

TGF-β-driven LIF expression influences neutrophil extracellular traps (NETs) and contributes to peritoneal metastasis in gastric cancer

Data from A C-X-C Chemokine Receptor Type 2–dominated Cross-talk Between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis

Impact of <i>GFRA1</i> gene reactivation by DNA demethylation on prognosis of patients with metastatic colon cancer

Tumor‐associated Macrophages Promote Angiogenesis and Lymphangiogenesis of Gastric Cancer

ANGPTL2+cancer-associated fibroblasts and SPP1+macrophages are metastasis accelerators of colorectal cancer